Correlates affecting survival in chronic hemodialysis patients: The combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results

Hemodialysis International

Volumn 12, Issue 4, 2008, Pages 450-462

  Capelli, John P ^a   Kushner, Harvey ^a  

^a OUR LADY OF LOURDES MEDICAL CENTER   (United States)

Author keywords

Anemia; Epoetin; ESRD; Survival

Indexed keywords

ALBUMIN; CALCIUM; HEMOGLOBIN; PHOSPHORUS; RECOMBINANT ERYTHROPOIETIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERFORMANCE MEASUREMENT SYSTEM; PREDICTION; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; TREATMENT DURATION;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MALEIMIDES; MIDDLE AGED; NEW JERSEY; PROPIONIC ACIDS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; SERUM ALBUMIN; SURVIVAL RATE; UNITED STATES;

EID: 53549103593     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00309.x     Document Type: Article

References (23)

1. The US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive Diseases; 2006. Available from: http://www.usrds.org/2007/pdf (accessed date: July 2007).
2. The 2006 Annual Dialysis Facility Report. The University of Michigan Kidney Epidemiology and Cost Center, August 2006.
3. Eggs DW. Mortality rates among dialysis patients in medicare's end-stage renal disease program. Am J Kid Dis. 1990; 15: 414-421.
4. Held PJ, Pauly MV, Diamond L. Survival analysis of patients undergoing dialysis. JAMA. 1987; 257: 645-650.
5. Lowrie EG, Teehan BP. Principles of prescribing dialysis therapy: Implementing recommendations from the national cooperative dialysis study. Kidney Int. 1983; 23(Suppl 13): 113-122.
6. Capelli JP, Kushner H, Camiscioli TS, et al. Factors affecting survival of hemodialysis patients utilizing urea kinetic modeling. Am J Nephrol. 1992; 12: 212-223.
7. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med. 2006; 355: 2085-2098.
8. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Eng J Med. 1998; 339: 584-590.
9. Evans RW, Raeler B, Manninen DL. Cooperative multicenter EPO clinical trial group: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA. 1990; 263: 825-830.
10. Guthrie M, Cardenas D, Eschback JW, et al. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol. 1993; 39: 97-102.
11. Canella G, LaCanna G, Sandrini M, et al. Renormalization of high cardiac output and left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol. 1990; 34: 272-278.
12. Pascual J, Teruel JL, Moya JL, et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis. A prospective study. Clin Nephrol. 1991; 35: 280-287.
13. Fellner SK, Lang RM, Newman A, et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int. 1993; 44: 1309-1315.
14. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(Suppl 3): S11-S145.
15. Capelli JP, Kushner H, Camiscioli TS. Effect of intradialytic-parenteral nutrition on mortality rates in end-stage renal disease care. Am J Kid Dis. 1994; 23: 808-816.
16. Ma JZ, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999; 10: 610-619.
17. Foley RN, Parfrey PS, Harneh JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage kidney disease. Am J Kidney Dis. 1996; 28: 53-61.
18. Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular morbidity and mortality: The experience of the lombardy dialysis registry. Nephrol Dial Transplant. 1998; 13: 1642-1644.
19. Morton CC. U.S. dialysis survival strategy. Ann Int Med. 1998; 128: 514-516.
20. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving chemotherapy: A survival study. J Clin Oncol. 2005; 23: 1-13.
21. Wright JR, Ung YC, Julian JA, et al. Randomized double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease related anemia. J Clin Oncol. 2007; 25: 1-16.
22. Drueke T, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Eng J Med. 2006; 355: 2071-2084.
23. Levin A. Understanding recent haemoglobin trials in CKD: Methods and lessons learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007; 22: 309-312.